Shengnuo Biotech announced that Meishan Huilong Pharmaceutical Technology Co., Ltd., a wholly-owned subsidiary of the company, recently received the “Pharmaceutical Production License” and “Pharmaceutical GMP Compliance Inspection Notice” approved and issued by the Sichuan Drug Administration. The “Pharmaceutical Production License” is valid until March 25, 2031. The scope of production includes two types of APIs that are limited to registration and use only; those that have passed the GMP compliance inspection this time are APIs for export use only, corresponding to 102 API workshops and production lines, and the inspection findings are in line with the requirements. Obtaining the above qualifications will consolidate the company's production management and quality compliance system, provide a guarantee for expanding overseas markets, and there is uncertainty about the impact on short-term business performance.

Shengnuo Biotech announced that Meishan Huilong Pharmaceutical Technology Co., Ltd., a wholly-owned subsidiary of the company, recently received the “Pharmaceutical Production License” and “Pharmaceutical GMP Compliance Inspection Notice” approved and issued by the Sichuan Drug Administration. The “Pharmaceutical Production License” is valid until March 25, 2031. The scope of production includes two types of APIs that are limited to registration and use only; those that have passed the GMP compliance inspection this time are APIs for export use only, corresponding to 102 API workshops and production lines, and the inspection findings are in line with the requirements. Obtaining the above qualifications will consolidate the company's production management and quality compliance system, provide a guarantee for expanding overseas markets, and there is uncertainty about the impact on short-term business performance.